Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of develo**
breast cancer (BC) and are found in~ 5% of unselected patients with the disease. BC …

In the past decade, significant progress was made in treating hormone receptor-positive
(HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast …

Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …

The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene,
including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and …

Importance Poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors have
revolutionized the treatment of patients with germlineBRCA1/2-associated breast cancer …

BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of
onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate …

Simple Summary The mechanisms of intrinsic and acquired resistance to CDK4/6 inhibitors
are poorly understood. Patients with HR+ MBC treated with CDK4/6i and antiestrogen …

Simple Summary CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are the established
first-line treatment for metastatic and advanced hormone receptor-positive breast cancer …

We review key topics in the management of estrogen receptor (ER)–positive human
epidermal growth factor receptor 2–negative breast cancer. The single biggest challenge in …

Breast cancers (BCs) arising in carriers of germline BRCA1 and BRCA2 pathogenic variants
(PV) have long been considered as indistinguishable biological and clinical entities …